Compositions for inhibiting virus entry and promoting virolysis, and methods thereof
View Patent ↗The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing compound. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing compound. The invention further includes a method of causing virolysis of a virus using the compositions described therein. The invention further includes a method of inhibiting virus entry using the compositions described therein.
1. A composition comprising a peptide of formula (II) or a salt thereof:
(I),
(SEQ ID NO: 2)
Arg Ile Asn Asn Ile X Trp Ser Glu Ala Met Met βA
Gln βA Cys-NH 2 ,
wherein: X is (2,4)-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxylic acid, and βA is beta-alanine.
2. The composition of claim 1 , further comprising at least one gold nanoparticle, wherein the at least one nanoparticle is complexed to the peptide of formula (II) through the Cys thiol group of SEQ ID NO:2.
3. The composition of claim 1 , further comprising at least one additional compound for treating viral infections.
4. The composition of claim 1 , wherein the peptide is encapsulated in a hydrogel.
5. A method of preparing a derivatized gold nanoparticle, wherein the gold nanoparticle is complexed with a binding molecule or a salt thereof, the method comprising:
contacting a solution of the binding molecule with the nanoparticle to generate a reaction system;
stirring the reaction system for an amount of time, whereby the derivatized gold nanoparticle is formed; and
isolating the derivatized gold nanoparticle from the reaction system,
wherein the binding molecule comprises a peptide of formula (II) or a salt thereof:
(II),
(SEQ ID NO: 2)
Arg Ile Asn Asn Ile X Trp Ser Glu Ala Met Met βA
Gln βA Cys-NH 2 ,
wherein X is (2,4)-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxylic acid, and βA is beta-alanine;
wherein the nanoparticle is complexed to the peptide of formula (II) through the Cys thiol group of SEQ ID NO:2.
6. A method of promoting virolysis of a virus in a mammal, wherein the virus is selected from the group consisting of human immunodeficiency virus type 1 (HIV-1), influenza, ebola and dengue, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising at least one pharmaceutically acceptable carrier and at least one gold nanoparticle, wherein the gold nanoparticle is complexed with a binding molecule or a salt thereof, wherein the binding molecule comprises:
a peptide of formula (II) or a salt thereof:
(II),
(SEQ ID NO: 2)
Arg Ile Asn Asn Ile X Trp Ser Glu Ala Met Met βA
Gln βA Cys-NH 2 ,
wherein X is (2,4)-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxylic acid, and βA is beta-alanine;
wherein the nanoparticle is complexed to the peptide of formula (II) through the Cys thiol group of SEQ ID NO:2;
whereby virolysis of the virus in the mammal is promoted.
7. The method of claim 6 , wherein the mammal is further administered at least one additional compound for treating viral infections.
8. The method of claim 6 , wherein the peptide is encapsulated in a hydrogel.
9. The method of claim 6 , wherein the mammal is human.
10. A method of reducing the rate of or inhibiting entry of a virus into a cell of a mammal, wherein the virus is selected from the group consisting of human immunodeficiency virus type 1 (HIV-1), influenza, ebola and dengue, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising at least one pharmaceutically acceptable carrier and at least one gold nanoparticle, wherein the gold nanoparticle is complexed with a binding molecule or a salt thereof, wherein the binding molecule comprises
a peptide of formula (II) or a salt thereof:
(II),
(SEQ ID NO: 2)
Arg Ile Asn Asn Ile X Trp Ser Glu Ala Met Met βA
Gln βA Cys-NH 2 ,
wherein X is (2,4)-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxylic acid, and βA is beta-alanine;
wherein the nanoparticle is complexed to the peptide of formula (II) through the Cys thiol group of SEQ ID NO:2;
whereby the entry of the virus into the cell of the mammal is inhibited or takes place at a reduced rate as compared to an untreated mammal.
11. The method of claim 10 , wherein the mammal is further administered at least one additional compound useful for treating viral infections.
12. The method of claim 10 , wherein the peptide is encapsulated in a hydrogel.
13. The method of claim 10 , wherein the mammal is human.
14. A method of reducing or treating infection of a virus in a mammal, wherein the virus is selected from the group consisting of human immunodeficiency virus type 1 (HIV-1), influenza, ebola and dengue, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising at least one pharmaceutically acceptable carrier and at least one gold nanoparticle, wherein the gold nanoparticle is complexed with a binding molecule or a salt thereof, wherein the binding molecule comprises
a peptide of formula (II) or a salt thereof:
(II),
(SEQ ID NO: 2)
Arg Ile Asn Asn Ile X Trp Ser Glu Ala Met Met βA
Gln βA Cys-NH 2 ,
wherein X is (2,4)-4-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)pyrrolidine-2-carboxylic acid, and βA is beta-alanine;
wherein the nanoparticle is complexed to the peptide of formula (II) through the Cys thiol group of SEQ ID NO:2;
whereby the infection of the virus in the mammal is reduced or treated.
15. The method of claim 14 , wherein the mammal is further administered at least one additional compound for treating viral infections.
16. The method of claim 14 , wherein the peptide is encapsulated in a hydrogel.
17. The method of claim 14 , wherein the mammal is human.